Genprex (NASDAQ: GNPX) is a clinical-stage,
gene-therapy company focused on the advancement of its lead drug candidate,
Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for
non-small cell lung cancer (“NSCLC”). An article discussing the company reads,
“Oncoprex is designed to interrupt cell signaling pathways that cause
replication and proliferation of cancer cells, to target and kill cancer cells
via receptor pathways, and to stimulate natural immune responses against
cancer. Oncoprex consists of the TUSC2 tumor suppressor gene encapsulated in a
positively charged lipid nanoparticle. It is injected intravenously,
specifically targeting cancer cells, which generally have a negative electrical
charge. Once Oncoprex is taken up into a cancer cell, the TUSC2 gene is
expressed in a protein that is capable of restoring certain defective functions
arising in the cancer cell (http://ibn.fm/zkW0b).”
To view the full article, visit http://ibn.fm/IpS2N
About Genprex Inc.
Genprex is a clinical-stage, gene-therapy company developing
potentially life-changing technologies for cancer patients based upon a unique
proprietary technology platform, including Genprex’s initial product candidate,
Oncoprex immunogene therapy for non-small cell lung cancer (“NSCLC”). Genprex’s
platform technologies are designed to administer cancer-fighting genes by
encapsulating them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where they express
proteins that are missing or found in low quantities. Oncoprex has a multimodal
mechanism of action whereby it interrupts cell-signaling pathways that cause
replication and proliferation of cancer cells, re-establishes pathways for
apoptosis, or programmed cell death, in cancer cells, and modulates the immune
response against cancer cells. Oncoprex has also been shown to block mechanisms
that create drug resistance. For more information, visit the company’s website
at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
